Bibliography
- Cunningham MJ, Macklin EA, Neufeld EJ, et al. Complications of β-thalassemia major in North America. Blood 2004;104:34-9
- Olivieri NF. The β-thalassemias. N Engl J Med 1999;341:99-109
- Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci 1998;850:227-31
- Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996;95:26-36
- Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 1994;331:574-8
- Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-61
- Rose C, Gattermann N, Glimm E, et al. Deferasirox (Exjade®, ICL670), the novel, once-daily oral iron chelator, is well tolerated and effective in treating transfusional iron overload in patients with a range of rare anaemias [abstract 22]. Haematologica 2006;91(Suppl 1)
- Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion 2007;47:1919-29
- Ceci A, Baiardi P, Felisi M, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002;118:330-6
- Cohen AR, Galanello R, Piga A, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003;102:1583-7
- Karnon J, Tolley K, Oyee J, et al. Cost–utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. Curr Med Res Opin 2008;24:1609-21
- Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-73
- Ferriprox. Summary of product characteristics. Apotex, 1999
- Abdelrazik N. Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience. Hematology 2007;12:577-85
- Aydinok Y, Nisli G, Kavakli K, et al. Sequential use of deferiprone and desferrioxamine in primary school children with thalassaemia major in Turkey. Acta Haematol 1999;102:17-21
- Galanello R, Kattamis A, Piga A, et al. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica 2006;91:1241-3
- Nick H. Deferasirox (Exjade®, ICL670) Preclinical overview. Semin Hematol 2007;44:S12-5
- Nick H, Acklin P, Lattmann R, et al. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem 2003;10:1065-76
- Nick H, Wong A, Acklin P, et al. ICL670A: preclinical profile. Adv Exp Med Biol 2002;509:185-203
- Glickstein H, Ben El R, Link G, et al. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood 2006;108:3195-203
- Wood JC, Otto-Duessel M, Gonzales I, et al. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Translational Res 2006;148:272-80
- Galanello R, Piga A, Alberti D, et al. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol 2003;43:565-72
- Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003;361:1597-602
- Piga A, Galanello R, Forni GL, et al. Randomized Phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006;91:873-80
- Daar S, Taher A, Pathare A, et al. Sustained protection from labile plasma iron (LPI) with the once-daily, oral iron chelator deferasirox (Exjade®, ICL670) in iron-overloaded β-thalassemia patients [abstract 1773]. Blood 2006;108(11)
- Porter J, Borgna-Pignatti C, Baccarani M, et al. Iron chelation efficiency of deferasirox (Exjade®, ICL670) in patients with transfusional hemosiderosis [abstract 2690]. Blood 2005;106(11)
- Galanello R, Piga A, Forni GL, et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in paediatric patients with β-thalassaemia major. Haematologica 2006;91:1343-51
- Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood 2006;107:3455-62
- Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 2008;80:168-76
- Vichinsky E, Onyekwere O, Porter J, et al. A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007;136:501-8
- Cappellini MD, Vichinsky E, Galanello R, et al. Long-term treatment with deferasirox (Exjade®, ICL670), a once-daily oral iron chelator, is effective in patients with transfusion-dependent anemias [abstract 2777]. Blood 2007;110(11)
- Porter JB, Cohen AR, Ford JM, et al. Impact of dose adjustments on serum ferritin (SF) levels during long-term treatment with once-daily, oral deferasirox (Exjade®, ICL670) [abstract 2778]. Blood 2007;110(11)
- Taher A, El-Beshlawy A, Al Jefri A, et al. Treatment with the once-daily, oral iron chelator deferasirox is effective and well tolerated in β-thalassaemia patients with a high iron burden [abstract 0808]. Haematologica 2007;92(Suppl 1)
- Gattermann N, Schmid M, Vassilieff D, et al. Severe iron overload in patients with myelodysplastic syndromes enrolled in a large study of deferasirox (Exjade®, ICL670) [abstract P129]. Leuk Res 2007;31(Suppl 1):S109-10
- Eleftheriou P, Tanner M, Pennell D, et al. Response of myocardial T2* to oral deferasirox monotherapy for 1 year in 29 patients with transfusion-dependent anaemias: a subgroup analysis [abstract 999]. Haematologica 2006;91(Suppl 1)
- Wood J, Thompson AA, Paley C, et al. Exjade reduces cardiac iron burden in chronically transfused β-thalassemia patients: an MRI T2* study [abstract 2781]. Blood 2007;110(11)
- Otto-Duessel M, Aguilar M, Nick H, et al. Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy. Exp Hematol 2007;35:1069-73
- Exjade (deferasirox) Summary of product characteristics. Novartis Pharma AG. 2006. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/exjade/H-670-PI-en.pdf accessed 15 July 2008
- Vichinsky E. Clinical application of deferasirox: practical patient management. Am J Hematol 2008;83:398-402
- Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther 2007;29:909-17
- Vichinsky E, Pakbaz Z, Onyekwere O, et al. Patient-reported outcomes of deferasirox (Exjade®, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis: substudy of a randomized open-label Phase II trial. Acta Haematol 2008;119:133-41
- Exjade basic prescribing information. Basel, Switzerland: Novartis Pharma AG 2006
- Gattermann N, Porter J, Lopes LF, et al. Consensus statement on iron overload in myelodysplastic syndromes. Hematol Oncol Clin North Am 2005;19(Suppl 1):18-25
- Leitch HA. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk Res 2007;31(Suppl 3):S7-9
- Rose C, Brechignac S, Vassilief D, et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM [abstract 249]. Blood 2007;110(11)
- Mahindra A, Bolwell B, Sobecks R, et al. Elevated pretransplant serum ferritin in autologous stem cell transplant [abstract 606]. Blood 2007;110(11)
- Platzbecker U, Germing U, Stumpf J, et al. The impact of transfusion-dependency on the outcome of patients with myelodysplastic syndromes (MDS) receiving allogeneic peripheral blood stem cell transplantation after myeloablative conditioning [abstract 1467]. Blood 2007;110(11)
- Pietrangelo A, Brissot P, Bonkovsky H, et al. Design of an ongoing Phase I/II open-label, dose-escalation trial using the oral chelator deferasirox to treat iron overload in HFE-related hereditary hemochromatosis (HH) [abstract 2680]. Blood 2007;110(11)
- Cohen AR. New advances in iron chelation therapy. Hematology Am Soc Hematol Educ Program 2006;42-7